Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. (March 2023)

• Record Type: Journal Article
• Authors: Kishan, Amar U.; Marco, Nicholas; Ma, Ting Martin; Steinberg, Michael L.; Sachdeva, Ankush; Cao, Minsong; Ballas, Leslie K.; Rietdorf, Emily; Telesca, Donatello; Weidhaas, Joanne B.
• Is Part Of: Clinical and translational radiation oncology. Volume 39(2023)
• Publication Date: 2023-03
• Subjects: SBRT -- Genito-urinary toxicity -- Germline biomarkers -- PROSTOX; Cancer -- Radiotherapy -- Periodicals; Oncology -- Periodicals; Cancer -- Radiotherapy; Oncology; Radiation Oncology; Neoplasms -- radiotherapy; Translational Medical Research; Periodicals; Electronic journals; Periodicals; 616.9940642
• DOI: 10.1016/j.ctro.2023.100594
• Languages: English
• ISSNs: 2405-6308

Abstract

Highlights: Genitourinary (GU) toxicity is a significant problem after short course radiotherapy (SBRT) for prostate cancer. Germline genetic biomarkers have been found to identify patients at significant increased risk of late GU toxicity. This genetic signature, PROSTOX, also identifies patients at increased risk of toxicity when SBRT is delivered after surgery. These findings validate the importance of PROSTOX in identifying patients at increased risk of GU toxicity after radiotherapy. Abstract: Predictors of genitourinary toxicity after post-prostatectomy radiotherapy remain elusive. A previously defined germline DNA signature (PROSTOX) has shown predictive ability for late grade ≥ 2 GU toxicity after intact prostate stereotactic body radiotherapy. We explore whether PROSTOX would predict toxicity among patients receiving post-prostatectomy SBRT on a phase II clinical trial.